SEC Form 10-Q Summary
Filing identity: The supplied filing is for Greatbatch, Inc., not Integer Holdings Corp. It covers the 13-week first quarter ended April 3, 2015, compared with the 13-week period ended April 4, 2014. The financial statements are unaudited and prepared under U.S. GAAP.
Business Context and Reporting Period
Greatbatch operated through two reportable segments: Greatbatch Medical, which designs and manufactures medical devices and components, and QiG, which develops medical device systems and related technologies. The company acquired CCC in August 2014; CCC contributed approximately $3.9 million of first-quarter 2015 revenue and $0.1 million of net income.
In April 2015, the company proposed spinning off Algostim, its spinal cord stimulation business, into a separate publicly traded company. Greatbatch Medical would continue manufacturing products for the proposed new entity.
Key Financial Metrics
| Metric | Q1 2015 | Q1 2014 | Change |
|---|---|---|---|
| Sales | $161.3 million | $174.3 million | Down 7% |
| Gross profit | $52.4 million | $57.6 million | Down 9% |
| Gross margin | 32.5% | 33.0% | Down 50 bps |
| Operating income | $9.4 million | $22.5 million | Down 58% |
| Operating margin | 5.8% | 12.9% | Down 710 bps |
| Net income | $8.0 million | $14.9 million | Down 46% |
| Diluted EPS | $0.31 | $0.58 | Down $0.27 |
| Adjusted operating income | $17.2 million | $22.3 million | Down 23% |
| Adjusted diluted EPS | $0.54 | $0.54 | Flat |
| Cash flow from operations | $7.3 million | $7.0 million | Up 5% |
| Capital expenditures | $15.4 million | $6.0 million | Higher investment |
Cash and equivalents were $67.0 million at April 3, 2015, down from $76.8 million at January 2, 2015. Working capital was $248.9 million and the current ratio was 3.85. Total debt was $185.0 million, consisting of a variable-rate term loan; no revolving credit facility borrowings were outstanding. The company had $300 million of revolver capacity available and remained in compliance with its debt covenants. Its adjusted EBITDA-to-interest ratio was 30.2x versus a 3.0x minimum, and its total leverage ratio was 1.45x versus a maximum of 4.5x.
Material Changes Versus the Prior Comparable Period
- Sales declined primarily because of a difficult prior-year comparison, approximately $5 million of revenue lost from cardiac product end-of-life programs, weakness in portable medical products, customer inventory management, and approximately $4 million of unfavorable currency translation.
- Greatbatch Medical sales fell 10% to $157.0 million. Cardiac/neuromodulation sales declined 12%, portable medical declined 29%, and vascular declined 21%. Orthopaedic sales increased 7% as reported and 18% on an organic constant-currency basis.
- QiG sales increased to $5.0 million from $0.7 million, substantially reflecting the CCC acquisition and new product activity.
- Gross margin declined because of lower volumes, product mix, contractual price concessions, and acquisition-related effects.
- Other operating expenses increased to $7.9 million from income of $0.2 million, primarily due to $6.5 million of capacity and capability investments and $0.5 million of orthopaedic optimization costs.
- SG&A increased 4% to $22.6 million, while net research, development and engineering expense declined 7% to $12.5 million.
- The effective tax rate fell to 18.5% from 32.4%, primarily because of $0.8 million of discrete tax benefits from audit settlements and a greater proportion of income in lower-tax jurisdictions.
- Foreign currency transaction gains improved by approximately $1.3 million, but foreign currency translation produced a $1.8 million comprehensive-income loss versus a $1.2 million gain in the prior-year quarter.
Guidance, Outlook, Risks and Unusual Items
Management maintained fiscal 2015 guidance of sales of $715 million to $730 million, but expected revenue toward the lower end because currency translation was projected to reduce revenue by approximately $10 million. Guidance included GAAP diluted EPS of $2.02 to $2.12, adjusted diluted EPS of $2.61 to $2.71, GAAP operating margin of 10.7% to 11.0%, adjusted operating margin of 13.7% to 14.0%, capital expenditures of $40 million to $50 million, and an approximately 25% GAAP effective tax rate.
Management expected approximately $22 million of 2015 GAAP operating adjustments, with an estimated after-tax impact of approximately $14 million. Proposed Algostim spin-off transaction costs of $8 million to $12 million were not included in guidance. Management targeted FDA approval of Algovita by the end of 2015; the FDA had deemed the application approvable subject to a satisfactory manufacturing inspection.
Cost and capacity initiatives remained significant. The 2014 capacity and capability program was expected to generate more than $20 million of annual savings, with $29 million to $34 million of expected expenses and $25 million to $27 million of expected capital investment. Orthopaedic optimization was expected to require $45 million to $48 million of expense and $30 million to $35 million of capital investment, with expected annual savings of $10 million to $15 million.
- Key risks include customer concentration, pricing pressure, product obsolescence, customer ordering variability, execution of plant transfers and cost programs, product quality and liability exposure, regulatory approvals, acquisitions, intellectual property, healthcare regulation, currency and interest-rate volatility, and litigation.
- Three customers represented 54% of sales, up from 48% in the prior-year quarter.
- The company had approximately $40.6 million of purchase commitments and $35.3 million of estimated future operating lease expense.
- Unrecognized tax benefits were approximately $1.9 million; up to $0.5 million could be reduced within the following 12 months.
- A voluntary field corrective action remained relevant for certain orthopaedic products; the company reported three potentially related complaints and no adverse events.
- The company had $90 million of unhedged floating-rate debt; a 100-basis-point LIBOR change would affect annual interest expense by approximately $0.9 million.
Investor Verification Checklist
- Verify the issuer name: the supplied filing is Greatbatch, Inc., although the request identifies Integer Holdings Corp.
- Reconcile reported GAAP results with adjusted operating income and adjusted EPS, including the treatment of restructuring, acquisition, investment, and tax-credit items.
- Monitor cardiac product end-of-life revenue losses, portable medical recovery, vascular inventory normalization, and the expected second-half product launches.
- Track execution, remaining costs, capital spending, and realized savings from manufacturing transfers and orthopaedic optimization.
- Confirm the timing, regulatory approvals, tax treatment, costs, and ongoing manufacturing arrangements associated with the proposed Algostim spin-off.
- Assess customer concentration, foreign-exchange exposure, variable-rate debt, hedge positions, and compliance with credit-facility covenants.